Horizon Discovery, which makes its money providing development expertise to drugmakers, has signed a deal with Otsuka Pharmaceutical to apply its technology to some early-phase treatments. Under the agreement, Horizon well lend out its tools for screening compounds and analyzing potential drug combinations, using technology it acquired in an $8 million buyout of Zalicus' ($ZLCS) CombinatoRx business earlier this year. The Otsuka deal is Horizon's first major partnership since pulling off a £68.6 million ($116.6) IPO in March. More